Fenfluramine for Dravet Syndrome: What a New Pooled
This fenfluramine dravet syndrome stratified analysis pools data from three phase 3 trials, demonstrating seizure reduction across most patient subgroups. The study highlights fenfluramine's safety profile and efficacy, providing key insights for…
Cannabidiol Effects on Cortical Excitability: Evidence from a Randomized, Double-Blind, Placebo-Controlled Study
This clinical trial evaluated CBD anti seizure activity and found no direct effect on cortical excitability or sedation in healthy adults. The study suggests CBD's benefit may depend on interactions with other drugs like clobazam. These findings…
CBD in Childhood Epilepsy: What the Evidence Actually Shows
Several randomized controlled trials demonstrate cannabidiol pediatric epilepsy dosing reduces seizures in syndromes like Lennox-Gastaut and Dravet. This review summarizes dosing, drug interactions, and safety monitoring for cannabidiol in pediatric…
CBD for Childhood Epilepsy: What the Evidence Actually Shows
A 2025 clinical update highlights cannabidiol pediatric epilepsy evidence showing meaningful seizure reduction in children with drug-resistant epilepsy. The review emphasizes dosing protocols and safety monitoring. Cannabidiol pediatric epilepsy…
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
Dravet syndrome is a severe pediatric epilepsy with drug-resistant seizures. This review focuses on ameliorating seizures in Dravet syndrome using newly approved and investigational therapies. Cannabinoid and gene-based treatments show promise in…
Cannabidiol as a New Treatment for Rare Forms of Epilepsy
New research highlights cannabidiol for epilepsy treatment as a promising option for therapy refractory epileptic encephalopathies. Cannabidiol shows potential in reducing seizures in rare epileptic syndromes like Dravet and Lennox-Gastaut. This…